$2.52
+0.00 (+0.00%)
Open$2.53
Previous Close$2.52
Day High$2.53
Day Low$2.52
52W High$6.20
52W Low$1.67
Volume—
Avg Volume8.0K
Market Cap6.05M
P/E Ratio—
EPS$-2.21
SectorBiotechnology
Analyst Ratings
Strong Sell
6 analysts
Price Target
+1,528.2% upside
Current
$2.52
$2.52
Target
$41.03
$41.03
$36.60
$41.03 avg
$68.97
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 6.2K | 52.2K | 1.35M |
| Net Income | -5,149,004 | -38,746,685 | -84,207 |
| Profit Margin | -83,520.0% | -79,344.0% | -6.2% |
| EBITDA | -5,140,355 | -40,830,579 | -111,401 |
| Free Cash Flow | — | — | -113,905 |
| Rev Growth | -88.0% | -88.0% | +20.4% |
| Debt/Equity | — | — | 1.56 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $210.39 | -0.18% | 88.1 | 372.39B |
| AMGN | Amgen Inc | $326.31 | -2.95% | 23.0 | 179.23B |
| GILD | Gilead Sciences Inc | $129.58 | -1.88% | 17.4 | 160.50B |
| VRTX | Vertex Pharmaceuticals Inc | $436.95 | -2.99% | 26.4 | 114.32B |
| REGN | Regeneron Pharmaceuticals | $698.25 | -2.05% | 16.7 | 73.89B |
| ALNY | Alnylam Pharmaceuticals Inc | $286.98 | -2.20% | 66.6 | 38.43B |